Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Mar 06, 2019 - Disappointing phase 3 drug results and a weaker-than-expected revenue outlook are weighing on these stocks.
Mar 06, 2019 - J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
Mar 04, 2019 - Okta's (OKTA) fourth-quarter fiscal 2019 top-line is likely to benefit from its solid customer base despite higher expenses.
Feb 21, 2019 - Disappointing data from Gilead Sciences and Sangamo weigh on investors, while one tiny stock challenges Allergan.
Feb 20, 2019 - Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Feb 19, 2019 - Corporate executives worried about workplace shootings are quietly installing gunfire-detection systems in U.S. offices and factories. Most don’t tell employees what the sensors are, for fear of alarming them.
Feb 15, 2019 - Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: AGN, release date:Feb 15, 2019
Feb 14, 2019 - Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Feb 05, 2019 - Under pressure over rising drug prices, pharmaceutical companies are pushing a new defense: They’re not raising prices to make money or to cover research costs, but rather to pay a cut to middlemen in the supply chain.